title: Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.
abstract: Up to 30% of patients who undergo radiation for intermediate- or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of luteinizing hormone-releasing hormone agonist) to primary radiotherapy (RT) for intermediate- or high-risk localized prostate cancer.
  
  
  
  A total of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) ≥ 10 ng/mL or Gleason ≥ 7, or (2) cT2a (International Union Against Cancer TNM 1997), with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread, with PSA ≤ 50 ng/mL, were centrally randomized 1:1 to either RT or RT plus AS started on day 1 of RT. Centers opted for one dose (70, 74, or 78 Gy). Biochemical DFS, the primary end point, was defined from entry until PSA relapse (Phoenix criteria) and clinical relapse by imaging or death of any cause. The trial had 80% power to detect hazard ratio (HR), 0.714 by intent-to-treat analysis stratified by dose of RT at the two-sided α = 5%.
  
  
  
  The median patient age was 70 years. Among patients, 74.8% were intermediate risk and 24.8% were high risk. In the RT arm, 407 of 409 patients received RT; in the RT plus AS arm, 403 patients received RT plus AS and three patients received RT only. At 7.2 years median follow-up, RT plus AS significantly improved biochemical DFS (HR, 0.52; 95% CI, 0.41 to 0.66; P < .001, with 319 events), as well as clinical progression-free survival (205 events, HR, 0.63; 95% CI, 0.48 to 0.84; P = .001). In exploratory analysis, no statistically significant interaction between treatment effect and dose of RT could be evidenced (heterogeneity P = .79 and P = .66, for biochemical DFS and progression-free survival, respectively). Overall survival data are not mature yet.
  
  
  
  Six months of concomitant and adjuvant AS improves biochemical and clinical DFS of intermediate- and high-risk cT1b-c to cT2a (with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread) prostatic carcinoma, treated by radiation.
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt. mbolla@chu-grenoble.fr.
authors.forename: Michel
authors.initials: M
authors.lastname: Bolla
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Philippe
authors.initials: P
authors.lastname: Maingon
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Christian
authors.initials: C
authors.lastname: Carrie
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Salvador
authors.initials: S
authors.lastname: Villa
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Petros
authors.initials: P
authors.lastname: Kitsios
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Philip M P
authors.initials: PM
authors.lastname: Poortmans
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Santhanam
authors.initials: S
authors.lastname: Sundar
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Elzbieta M
authors.initials: EM
authors.lastname: van der Steen-Banasik
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: John
authors.initials: J
authors.lastname: Armstrong
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Bosset
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Fernanda G
authors.initials: FG
authors.lastname: Herrera
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Bradley
authors.initials: B
authors.lastname: Pieters
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Annerie
authors.initials: A
authors.lastname: Slot
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Amit
authors.initials: A
authors.lastname: Bahl
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Rahamim
authors.initials: R
authors.lastname: Ben-Yosef
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Dirk
authors.initials: D
authors.lastname: Boehmer
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Christopher
authors.initials: C
authors.lastname: Scrase
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Laurette
authors.initials: L
authors.lastname: Renard
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Emad
authors.initials: E
authors.lastname: Shash
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Corneel
authors.initials: C
authors.lastname: Coens
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Alphonsus C M
authors.initials: AC
authors.lastname: van den Bergh
authors.affiliation: Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon-Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der Steen-Banasik, Arnhem Radiotherapy Institute, Arnhem; Bradley Pieters, University of Amsterdam, Amsterdam; Annerie Slot, Radiotherapeutisch Instituut Friesland, Leeuwarden; Alphonsus C.M. van den Bergh, University of Groningen, Groningen, the Netherlands; Santhanam Sundar, Nottingham University Hospitals National Health Service Trust-City Hospital, Nottingham; Amit Bahl, University Hospitals Bristol National Health Service Foundation Trust-Bristol Haematology and Oncology Centre, Bristol Avon; Christopher Scrase, Ipswich Hospital National Health Service Trust, Ipswich, United Kingdom; John Armstrong, St Luke's Hospital, Dublin, Ireland; Fernanda G. Herrera, University Hospital of Lausanne, Lausanne, Switzerland; Rahamim Ben-Yosef, Rambam Health Care Campus, Haïfa, Israel; Dirk Boehmer, Charite-Universitaetsmedizin Berlin-Campus Mitte, Berlin, Germany; Laurette Renard, Cliniques Universitaires Saint Luc; Emad Shash, Corneel Coens, and Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; and Emad Shash, Cairo University, Cairo, Egypt.
authors.forename: Laurence
authors.initials: L
authors.lastname: Collette
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000401:mortality / Q000628:therapy*; D011879:Radiotherapy Dosage
chemical_list: D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen